James Galloway

12.8k citations
278 papers · 5.5k · 4 hit papers · h-index 37

Impact in

  • Rheumatology top 0.2%
    • Rheumatoid Arthritis Research and Therapies
    • Systemic Lupus Erythematosus Research
    • Spondyloarthritis Studies and Treatments
  • Hematology top 1%
    • Autoimmune and Inflammatory Disorders Research

Papers in

    • Rheumatoid Arthritis Research and Therapies 133
    • Systemic Lupus Erythematosus Research 52
    • Spondyloarthritis Studies and Treatments 20
    • Autoimmune and Inflammatory Disorders Research 41

James Galloway

238 papers receiving 5.3k citations

James Galloway's Hit Papers

Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician 2024 · 58 citations
580+5+11Years since publication100200300400500

Peers

James Galloway
Comparison fields: 5 of 153
  • Rheumatology 2.7k
  • Hematology 1.1k
  • Immunology 986
  • Genetics 476
  • Infectious Diseases 816
Replace Kath Watson with:
Kath Watson United Kingdom
Roberto Caporali Italy
Sindhu R. Johnson Canada
Fenglong Xie United States
Sofía Ramiro Netherlands
Loreto Carmona Spain
Karim Raza United Kingdom
María A. López-Olivo United States
Andreas Kronbichler Austria
Christopher J Edwards United Kingdom
James Galloway relative to Kath Watson United Kingdom Kath Watson's profile →
Citations per field
00.5×6.5×
Kath Watson · 1×
Citations per year

Countries citing papers authored by James Galloway

Since Specialization
Citations

This map shows the geographic impact of James Galloway's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Galloway with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Galloway more than expected).

Fields of papers citing papers by James Galloway

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Galloway. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Galloway. The network helps show where James Galloway may publish in the future.

Co-authors

The 25 scholars most cited alongside James Galloway, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with James Galloway Line = papers co-authored together James Galloway links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 278 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)
Hit paper breakdown →
2009532
2
Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly
Hit paper breakdown →
2010496
3 2019192
4 2016171
5 2011145
6 2020127
7 2012124
8 2018121
9 2020113
10 2020112
11 2012109
12 201796
13 201295
14 202185
15 201684
16 201883
17 201882
18 198579
19
JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications
Hit paper breakdown →
202375
20 201872

About James Galloway

James Galloway is a scholar working on Rheumatology, Hematology, Epidemiology, Immunology and Infectious Diseases, having authored 278 papers that have together received 5.5k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (133 papers), Systemic Lupus Erythematosus Research (52 papers), Autoimmune and Inflammatory Disorders Research (41 papers), Chronic Lymphocytic Leukemia Research (24 papers), Spondyloarthritis Studies and Treatments (20 papers), Lymphoma Diagnosis and Treatment (17 papers), COVID-19 Clinical Research Studies (17 papers) and Biosimilars and Bioanalytical Methods (14 papers). The work is most often cited by research in Rheumatology (2.7k citations), Hematology (1.1k citations), Immunology (986 citations), Genetics (476 citations) and Infectious Diseases (816 citations). James Galloway has collaborated with scholars based in United Kingdom, United States and Italy. Frequent co-authors include Kimme L Hyrich, Mark Lunt, Deborah Symmons, Kath Watson, William G Dixon, Andrew Ustianowski, Katie Bechman, Sam Norton, Sujith Subesinghe and Louise Mercer. Their work appears in journals such as Lara D. Veeken, Annals of the Rheumatic Diseases, The Journal of Rheumatology, RMD Open and Arthritis & Rheumatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact